Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02630693
• Other study ID #: MA38
• Status: Completed
• Phase: Phase 2
• Start date: April 8, 2016
• Est. completion date: November 29, 2023

Study information

• Verified date: November 2023
• Source: Canadian Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing regimen of 125 mg daily for 21 days out of a 28 day cycle in combination with endocrine therapy.

Description:

The standard or usual treatment of this type of breast cancer is endocrine therapy. Palbociclib is a new type of drug for breast cancer. Laboratory tests as well as studies in animals and people show that it may help slow the growth of breast cancer. The most widely tested regimen of Palbociclib for patients with metastatic/advanced breast cancer is 125 mg every day for 21 days out of a 28 day cycle in combination with standard endocrine (hormone) therapy. This study explores if administering a lower dose of palbociclib - 100 mg given every day of a 28 day cycle in combination with standard endocrine (hormone) therapy - may result in more tumour shrinkage and be better tolerated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: November 29, 2023
• Est. primary completion date: August 15, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Premenopausal and postmenopausal women 18 years of age or older.

• Histologically confirmed adenocarcinoma of the breast, with ER positive and HER2 negative status based on local testing on most recent pathological tumour specimen.

• Patients must satisfy the following criteria for prior therapy:

• Progressed during treatment or within 12 months of completion of adjuvant endocrine therapy or

• Progressed during prior endocrine therapy for advanced/metastatic disease. Note:

'Progressed during endocrine therapy' means that the patient progressed while on or within 1 month after discontinuation of endocrine therapy.

• One line of chemotherapy for advanced/metastatic disease (regardless of prior adjuvant chemotherapy use) is allowed in addition to endocrine therapy.

• Patients must have evidence of disease to be eligible for the study, but measurable disease is not mandatory.

• For those patient with measureable disease who will be included in the response assessment, the following criteria must apply:

• X-ray = 20 mm

• Spiral CT scan or physical exam = 10 mm (lymph nodes must be = 15 mm in the short axis)

• Conventional CT scan, MRI = 20 mm

• Measurable lesions must be outside a previous radiotherapy field if they are the sole site of disease, unless disease progression has been documented.

Tumor lesions previously irradiated or subjected to other loco regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented.

• Eastern Cooperative Oncology Group (ECOG) 0-2.

• Adequate organ and bone marrow function as defined by:

• ANC = 1,500/mm3 (1.5 x 109/L)

• Platelets = 100,000/mm3 (100 x 109/L)

• Serum creatinine = 1.5 x ULN or estimated creatinine clearance =60 ml/min as calculated using the method standard for the institution;

• Total serum bilirubin = 1.5 x ULN (<3 ULN if Gilbert's disease).

• Patient must agree to provide tumour tissue from the most recent pathological tumour specimen.

• Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French

• Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate

• Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits placed on patients being considered for this trial.

• In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working days of patient randomization.

• Women of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria:

• Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term.

• Patients with symptomatic CNS involvement, meningeal or parenchymal, that is uncontrolled or requires steroids.

• Prior treatment with any CDK 4/6 inhibitor.

• Prior treatment with mTOR inhibitors.

• Active second malignancy, regardless of ongoing treatment.

• Any concurrent medical condition that in the opinion of the investigator would interfere with the safe administration of the study drug and participation in the study.

• Participation in a prior anti-cancer investigational study within 30 days prior to enrollment.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Palbociclib 100mg
100mg PO daily
• Palbociclib 125mg
125mg PO daily 3 weeks out of 4
• Fulvestrant or Tamoxifen or Aromatase Inhibitor
given at the standard doses/schedules

Locations

Country	Name	City	State
Canada	BCCA - Abbotsford Centre	Abbotsford	British Columbia
Canada	Royal Victoria Regional Health Centre	Barrie	Ontario
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	QEII Health Sciences Centre	Halifax	Nova Scotia
Canada	Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Ontario
Canada	Cancer Centre of Southeastern Ontario at Kingston	Kingston	Ontario
Canada	The Moncton Hospital	Moncton	New Brunswick
Canada	CHUM - Hopital Notre-Dame	Montreal	Quebec
Canada	Hopital du Sacre-Coeur de Montreal	Montreal	Quebec
Canada	The Jewish General Hospital	Montreal	Quebec
Canada	Stronach Regional Health Centre at Southlake	Newmarket	Ontario
Canada	Lakeridge Health Oshawa	Oshawa	Ontario
Canada	Ottawa Hospital Research Institute	Ottawa	Ontario
Canada	CHA-Hopital Du St-Sacrement	Quebec City	Quebec
Canada	Allan Blair Cancer Centre	Regina	Saskatchewan
Canada	Centre hospitalier universitaire de Sherbrooke	Sherbrooke	Quebec
Canada	Niagara Health System	St. Catharines	Ontario
Canada	Dr. H. Bliss Murphy Cancer Centre	St. John's	Newfoundland and Labrador
Canada	BCCA - Fraser Valley Cancer Centre	Surrey	British Columbia
Canada	University Health Network	Toronto	Ontario
Canada	BCCA - Vancouver Cancer Centre	Vancouver	British Columbia
Canada	Windsor Regional Cancer Centre	Windsor	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Canadian Cancer Trials Group	Pfizer

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival Using the RECIST 1.1 Criteria	progression free survival (PFS) is defined as time from randomization to progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	2 years
Secondary	Number of Participants With Response or No Response	Response rate = Number of (Complete response + partial response) / total treated patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	2 years
Secondary	Duration of Response	For patients with complete or partial response, duration of response is defined as days from first recorded response to the first date of recurrent or progression or death.	2 years
Secondary	Overall Survival	Time from randomization to death of any cause.	2 years